Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 18%
Buy 29%
Hold 53%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care's financial outlook is bolstered by a significant increase in pharmacy channel revenue, which represented 7% of US sales and saw a sequential growth of approximately 100%, contributing positively to overall top-line performance. Projections indicate a steady growth in US pump shipments of 10-11% year-over-year, with a noteworthy increase in renewal pump shipments and a anticipated return to positive growth in new patient starts, driven by greater Medication Administration Device (MDI) conversions and enhanced pharmacy access. Additionally, revenue forecasts suggest modest growth for 2026 and 2027, reflecting a confident trajectory as the company continues to expand its presence in the durable insulin pump market.

Bears say

Tandem Diabetes Care's revenue forecast for 2026 has been slightly reduced to $1.07 billion, with expected negative EBITDA ranging from -2% to -1% of revenue, highlighting potential struggles in profitability. US revenue guidance indicates a headwind of approximately $70–$80 million from Pay-Go pump shipments, compounded by anticipated flat to slightly declining new patient starts in the US market. Additional risks include competitive challenges that may impact new patient acquisitions, difficulties in securing favorable pharmacy channel contracts, and the possibility that the expected profit expansion from the newly launched Mobi pump does not materialize.

TNDM has been analyzed by 17 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 29% recommend Buy, 53% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 17 analysts, TNDM has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.